ReviewBiomedicines2022
Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions.
Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- Evaluation of [The Prostate · 2026Observational
- Fluid shear stress as a co-stimulatory cue to enhance T cell priming and restore activation in cancer patient T cells.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Review
- Tumor microenvironment-mediated immune evasion and resistance in prostate cancer: mechanisms, cross-talk, and therapeutic opportunities.Clinical and experimental medicine · 2025Review
- Review
- Immunomodulation and Immunotherapy for Patients with Prostate Cancer: An Up-to-Date Review.Biomedicines · 2025Review
- A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer.Cancer immunology research · 2025Article
- Bone-Targeting Radionuclides in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review on Radium-223 Chloride (Alpharadin) in Combination with Other Therapies.Diagnostics (Basel, Switzerland) · 2024Review
- A Phase 0 Study to Assess the Biodistribution and Pharmacokinetics of a Radiolabeled Antibody Targeting Human Kallikrein 2 in Participants with Metastatic Castration-Resistant Prostate Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Effect of GnRH Active Immunisation on Reproductive Performance of Male Sprague Dawley Rats.International journal of molecular sciences · 2024Article
- Immunome profiling in prostate cancer: a guide for clinicians.Frontiers in immunology · 2024Review
- Androgen receptor agonist and antagonist reduce response of cytokine-induced killer cells on prostate cancer cells.Journal of cellular and molecular medicine · 2023Article
- Probing the Relationship Between the Human Gut Microbiome and Prospects of Prostate Cancer: A Systematic Review.Cureus · 2023Review
- Contemporaneous and upcoming trends in immunotherapy for prostate cancer: review.Annals of medicine and surgery (2012) · 2023Article
- Cell-free DNA in the management of prostate cancer: Current status and future prospective.Asian journal of urology · 2023Review
- Targeting the Interplay of Independent Cellular Pathways and Immunity: A Challenge in Cancer Immunotherapy.Cancers · 2023Review
- A review of strategies to overcome immune resistance in the treatment of advanced prostate cancer.Cancer drug resistance (Alhambra, Calif.) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The advent of immunotherapy has revolutionized cancer treatment. Unfortunately, this has not been the case for metastatic castration-resistant prostate cancer (mCRPC), likely due to the heterogeneous and immune-suppressive microenvironment present in prostate cancer. The identification of molecular biomarkers that could predict response to immunotherapy represents one of the current challenges in this clinical scenario. The management of advanced castration-resistant prostate cancer is rapidly evolving and immunotherapy treatments, mostly consisting of immune checkpoint inhibitors combinations, BiTE
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.